Trials / Completed
CompletedNCT05741619
Long-term Follow up of Patient With Anti-GABAbr Antibodies Associated-encephalitis.
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 70 (actual)
- Sponsor
- Hospices Civils de Lyon · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
First described in 2010, GABA-B-receptor antibodies-associated encephalitis is a disease with a severe vital and functional prognosis. Indeed, functional status is mostly altered by encephalitis and it induced consequences while vital status is mostly engaged by cancer very often associated in the course of the disease, mostly small-cell lung cancer (SCLC). While knowledge is growing on clinical features at each stage of the disease, long-term outcome data is still lacking even if known to be pejorative. In this study, we aimed to describe long-term follow up of all patients who were diagnosed a GABAb-receptor antibodies-associated encephalitis in the French Paraneoplastic Neurological Syndrome Reference Center until now.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Long-term outcome | Autonomy, physical examination, behavioural disorders |
Timeline
- Start date
- 2022-01-01
- Primary completion
- 2022-06-01
- Completion
- 2022-09-01
- First posted
- 2023-02-23
- Last updated
- 2023-02-23
Locations
1 site across 1 country: France
Source: ClinicalTrials.gov record NCT05741619. Inclusion in this directory is not an endorsement.